- Bristol-Myers Squibb Company stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
Bristol-Myers Squibb Company stock price
Bristol-Myers Squibb Company latest news:
Bristol-Myers's stock surges toward 18-month high after Morgan Stanley turns bullish
Bristol-Myers Squibb Co.'s stock shot up 4.1% toward an 18-month high in morning trade Thursday, after Morgan Stanley turned bullish on the drugmaker, for the first time in 18 months, citing "compelling" immuno-oncology growth prospects. Analyst David Risinger raised his rating to overweight, after being at equal weight since Aug. 5, 2016, and boosted his stock price target to $78 from $63. Risinger said after he "dug deeper" into the company's release of the phase 3 Checkmate-227 study of Opdivo plus Yervoy combination versus chemotherapy, his investment thesis has changed: "We have greater confidence that Bristol's Opdivo + Yervoy combination regimen can play a meaningful role in first-line lung cancer, which is the largest cancer market." The stock was on track to close at the highest level since Aug. 4, 2016. It has now run up 11.5% over the past three months, while the SPDR Health Care Select Sector ETF has gained 4.3% and the S&P 500 has climbed 5.6%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Valentine's Day deal is true love for Nektar and Bristol-Myers
The deal limits Bristol-Myers' upfront payments while giving the drugmaker a cut of promising new drug NKTR-214. A new deal between Bristol-Myers Squibb Co. and Nektar Therapeutics (NKTR) came up candy hearts and roses for investors, sending Nektar shares up 12.5% and Bristol-Myers shares up 2.8% in heavy Wednesday trade. The deal is structured in a relatively complex way, effectively serving to limit Bristol-Myers' upfront payments while giving the drugmaker a cut of net profits...
Bristol-Myers Squibb claims 'breakthrough' lung-cancer treatment
Bristol-Myers Squibb is claiming a "breakthrough" in lung-cancer research with a potential alternative treatment to chemotherapy.
Bristol-Myers touts lung cancer breakthrough, but critics cry foul
Bristol-Myers shares drop 2.3% after company's overhaul of its clinical trial design is criticized. Bristol-Myers Squibb Co. (BMY) showed off positive results for a late-stage clinical trial early Monday, which the company said showed its drug combination worked but also advanced the scientific understanding of how to treat lung cancer-- and potentially other types of cancer, too. The results are "a breakthrough in cancer research," as well as for advanced lung cancer patients, Chief...
Bristol-Myers surges 5.6% on advanced lung cancer trial results, Q4 earnings
Bristol-Myers Squibb Co.(BMY) shares surged 5.6% in premarket trade on Monday after the company reported positive results for its Opdivo and Yervoy cancer drug combination in a late-stage clinical trial, along with fourth-quarter profit and revenue beats. In the phase 3 trial, the two-drug combination improved progression-free survival in patients with advanced lung cancer as compared with chemotherapy. The trial will continue because an interim analysis looking at overall...
BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb
* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY
BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE
Merck leaps past rivals with latest lung cancer drug results
Shares of rivals Bristol-Myers Squibb and Roche drop on the news. Merck& Co. Inc. shares surged 7% in extremely heavy trade Tuesday after the company announced that its key cancer drug Keytruda had positive results in a late-stage clinical trial for advanced lung cancer. Keytruda has already been approved for this indication, last year.
Bristol-Myers sees $3 billion tax hit in fourth quarter 2017
Bristol-Myers Squibb Co(BMY) will record a $3 billion charge in the fourth quarter of 2017 as a result of the U.S. tax reform law passed last month, the drugmaker said in a regulatory filing on Friday. The expense is primarily related to taxes on unremitted offshore earnings, the company said.
BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting ...
Bristol-Myers Squibb Co(BMY): * BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT. * Bristol-Myers Squibb Co(BMY) - BRISTOL-MYERS SQUIBB WILL MAKE AN UPFRONT PAYMENT OF $40 MILLION TO ONO.
BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment
* BRISTOL-MYERS SQUIBB GRANTED EXCLUSIVE LICENSE BY ONO
PHARMACEUTICAL FOR MULTIPLE PROGRAMS TARGETING
IMMUNO-SUPPRESSIVE FACTORS IN THE TUMOR MICROENVIRONMENT
BRIEF-U.S. FDA Accepts Bristol-Myers Squibb’S Application For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab)
Bristol-Myers Squibb Co(BMY): * U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS BRISTOL-MYERS SQUIBBS APPLICATION FOR OPDIVO PLUS YERVOY IN INTERMEDIATE- AND POOR-RISK PATIENTS WITH ADVANCED RENAL CELL CARCINOMA AND GRANTS PRIORITY REVIEW. * Bristol-Myers Squibb Co (BMY) - APPLICATION HAS AN ACTION DATE OF APRIL 16, 2018.
Bristow Group IncBRS
Brixmor Property Group Inc.BRX
Broadridge Financial SolutionsBR
Brookdale Senior Living Inc.BKD
Brookfield Asset Management IncBAM
Brookfield Canada Office PropertiesBOXC
Brookfield DTLA Inc.DTLA^
Brookfield Global Listed Infrastructure Income FunINF
Brookfield High Income Fund Inc.HHY
Brookfield Infrastructure Partners LPBIP